Sacibertinib clinical trials
Also written Hemay022.
How each study uses sacibertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sacibertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- Hemay022
- 2
Studies by the year they started
4 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Tianjin Hemay Pharmaceutical Co., Ltd (3) · Tianjin Hemay Oncology Pharmaceutical Co., Ltd (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses sacibertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast CancerRecruitingPhase 3Tianjin Hemay Pharmaceutical Co., LtdNCT06313983Written as Hemay022+AI
- Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast CancerCompletedPhase 1Tianjin Hemay Pharmaceutical Co., LtdNCT03308201Written as Hemay022+exemestane
- Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast CancerCompletedPhase 1Tianjin Hemay Pharmaceutical Co., LtdNCT02476539Written as Hemay022
- A Food-Effect Study of Hemay022 in Healthy ParticipantsStatus unknownPhase 1Tianjin Hemay Oncology Pharmaceutical Co., LtdNCT04673474Written as Hemay022
Codes
What other systems call sacibertinib · ClinicalTrials.gg INT017036
- UNII (FDA) K9S2RGS5TKSACIBERTINIBOne source FDA
- NCI Thesaurus C203119SacibertinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | K9S2RGS5TK | SACIBERTINIB | One source FDA |
| NCI Thesaurus | C203119 | Sacibertinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.